Risk and reward in the orphan drug industry
Thanks to a combination of scientific advances and economic incentives, the development of therapeutics to treat rare or orphan diseases has grown dramatically in recent years. With the advent of Food and Drug Administration–approved gene therapies and the promise of gene editing, many experts belie...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Portfolio Management Research
2019
|
| Online Access: | View Fulltext in Publisher |